Literature DB >> 6644024

Definition of a common leukocyte cell-surface antigen (Lp95-150) associated with diverse cell-mediated immune functions.

P G Beatty, J A Ledbetter, P J Martin, T H Price, J A Hansen.   

Abstract

We have described a monoclonal antibody, designated 60.3, which reacts with a cell surface antigen expressed by most peripheral blood and bone marrow leukocytes. Immunoprecipitation showed at least three major components with relative m.w. of 95,000, 130,000, and 150,000 under reducing conditions. Antibody 60.3 inhibited several cell-mediated immune functions. The lytic activity of both cytotoxic T cells and natural killer cells was blocked in the presence of the antibody. The proliferative responses of T cells stimulated by soluble antigens, mitogens, or allogeneic cells were inhibited when antibody 60.3 was added at the initiation of culture, but not when added after 48 hr. Antibody 60.3 also blocked the migration of neutrophilic granulocytes. The antigen identified by antibody 60.3 thus appears to be involved in a membrane-dependent cell activation pathway that is common to diverse functional systems and is shared by both lymphoid and myeloid cells.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6644024

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  85 in total

1.  Neutrophil adherence to human endothelium in vitro occurs by CDw18 (Mo1, MAC-1/LFA-1/GP 150,95) glycoprotein-dependent and -independent mechanisms.

Authors:  G A Zimmerman; T M McIntyre
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

2.  Analysis of gene-dosage effects on the expression of CD18 by trisomy 21 lymphoblastoid cell-lines using a statistical model to fit flow cytometry profiles.

Authors:  W G Bardsley; B P McMurray; A Robson; S D'Souza; G M Taylor
Journal:  Hum Genet       Date:  1990-12       Impact factor: 4.132

3.  Inhibition of leukocyte adherence by anti-CD18 monoclonal antibody attenuates reperfusion injury in the rabbit ear.

Authors:  N B Vedder; R K Winn; C L Rice; E Y Chi; K E Arfors; J M Harlan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

4.  Effects of leukotriene B4 in the human lung. Recruitment of neutrophils into the alveolar spaces without a change in protein permeability.

Authors:  T R Martin; B P Pistorese; E Y Chi; R B Goodman; M A Matthay
Journal:  J Clin Invest       Date:  1989-11       Impact factor: 14.808

5.  Neutrophils migrate across intestinal epithelium using beta2 integrin (CD11b/CD18)-independent mechanisms.

Authors:  K M Blake; S O Carrigan; A C Issekutz; A W Stadnyk
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

6.  Leptospira icterohemorrhagiae and leptospire peptidolgycans induce endothelial cell adhesiveness for polymorphonuclear leukocytes.

Authors:  A Dobrina; E Nardon; E Vecile; M Cinco; P Patriarca
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

7.  Activation of polymorphonuclear leukocytes reduces their adhesion to P-selectin and causes redistribution of ligands for P-selectin on their surfaces.

Authors:  D E Lorant; R P McEver; T M McIntyre; K L Moore; S M Prescott; G A Zimmerman
Journal:  J Clin Invest       Date:  1995-07       Impact factor: 14.808

8.  Successful treatment of canine leukocyte adhesion deficiency by foamy virus vectors.

Authors:  Thomas R Bauer; James M Allen; Mehreen Hai; Laura M Tuschong; Iram F Khan; Erik M Olson; Rima L Adler; Tanya H Burkholder; Yu-Chen Gu; David W Russell; Dennis D Hickstein
Journal:  Nat Med       Date:  2007-12-23       Impact factor: 53.440

9.  Human polymorphonuclear leucocytes stimulated by tumour necrosis factor-alpha show increased adherence to extracellular matrix proteins which is mediated via the CD11b/18 complex.

Authors:  H L Thompson; K Matsushima
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

10.  Leukotriene B4-induced hyperadhesiveness of endothelial cells for neutrophils: relation to CD54.

Authors:  J E Palmblad; R Lerner
Journal:  Clin Exp Immunol       Date:  1992-11       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.